All In Biotech

Drug Trial Radar · NCT05884255

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Randomized, Open, Positive Control Phase III Clinical Trial of Lutetium (177Lu) Oxodotreotide Injection Combined With Standard-dose Long-acting Octreotide Versus High-dose Long-acting Octreotide in the Treatment of Somatostatin Receptor-positive Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Jul 6, 2023

Primary completion

Dec 2026

Study completion Oct 2030

Sponsor

Sponsor type
Industry
First posted
Jun 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.

Conditions

  • Advanced Gastroenteropancreatic Neuroendocrine Tumor

Interventions

  • Lutetium (177Lu) Oxodotreotide Injection;long-acting OctreotideDrug

    Lutetium (177Lu) Oxodotreotide Injection combined with standard-dose long-acting Octreotide.

  • long-acting OctreotideDrug

    High-dose long-acting Octreotide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) assessed by BICRTime frame: Up to 1 year follow-up

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Tianjin University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.